If scar appearance doesn't improve then what's the Cometic...

If scar appearance doesn't improve then what's the Cometic use?
They say they expect it to improve over a longer period (3 months wasn't long enough even though it demonstrated huge composition change), but more importantly, the possibility is that it will work brilliantly for new scars - such as those that occur when undergoing an operation. Check out of hospital the next day - here's your tube of 9465 to heal that scar perfectly!

if 6302 is so good why they bother to change to the bloody 9465?
SNT-9465 has been specifically developed to allow for daily application, offering a more intensive and consistent inhibition of lysyl oxidase (LOX) enzymes, which play a central role in scar formation. This is a significant improvement over SNT-6302, which was administered three times per week. The enhanced tolerability of SNT-9465 makes it more suitable for daily use, potentially leading to better patient compliance and outcomes.

While SNT-6302 demonstrated promising results in remodeling mature scars, SNT-9465 is designed to target more recent hypertrophic scars (less than 24 months old). This focus aims to maximize therapeutic benefits by intervening earlier in the scarring process, potentially leading to more significant improvements in scar appearance and physical characteristics.

The development of SNT-9465 builds upon the findings from the SOLARIA2 trial involving SNT-6302, which showed significant reductions in collagen content and structural improvements in scar tissue. Leveraging these insights, Syntara's drug discovery team optimized the formulation to enhance anti-scarring efficacy while maintaining a favorable safety profile. The shift from SNT-6302 to SNT-9465 represents Syntara's commitment to advancing scar treatment by developing a more effective, user-friendly, and clinically versatile therapy

I'll take what the doctors working in scarring say over the analysts any day:
To our knowledge, this study represents the first demonstration of a safe and effective pharmaceutical intervention that significantly improves the molecular composition of established scar extracellular matrix in humans. Pan-lysyl oxidase inhibition therefore represents a potential paradigm shift for the amelioration of scarring.